# Inspire Medical Systems, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Inspire Medical Systems, Inc.). ## Overview Inspire Medical Systems develops and commercializes a minimally invasive neurostimulation therapy for obstructive sleep apnea. Its proprietary Inspire system senses breathing and delivers mild hypoglossal nerve stimulation to keep the airway open, and it is sold primarily to hospitals and ambulatory surgery centers in the U.S. with additional international distribution. ## Products & services • Inspire system for moderate to severe OSA • Inspire V next-generation system • Implantable neurostimulation therapy and related components • Physician training, practice development, and patient support • Direct-to-consumer and provider education programs - **Inspire therapy systems** (95%) — Implantable neurostimulation systems used to treat moderate to severe OSA. - **Next-generation Inspire V** (3%) — The newer platform launched in the U.S. to expand adoption and upgrade the installed base. - **International distribution sales** (2%) — Sales through distributors in selected Asia-Pacific markets and other non-U.S. countries. - Inspire system for moderate to severe obstructive sleep apnea - Inspire V next-generation neurostimulation platform - Implantable device, sensing, and stimulation components - Clinical training and practice development support - Patient education and direct-to-consumer awareness programs ## Customers The company sells to hospitals and ambulatory surgery centers, which are the purchasing entities for the procedure, while physicians and sleep centers drive patient identification and adoption. Reimbursement from commercial insurers, Medicare, Medicare Advantage, and government programs is central to customer purchasing decisions because the therapy is typically used in reimbursed care pathways. - **Hospitals and ambulatory surgery centers** (primary) — Primary purchasing customers that acquire the Inspire system for implantation procedures and need reimbursement support. - **ENT physicians and sleep centers** (primary) — Clinical referral and procedure-driving users who identify eligible OSA patients and influence adoption. - **Commercial payors and Medicare beneficiaries** (primary) — Patients covered by insurers and Medicare who need positive coverage policies for treatment access. - **International distributors** (secondary) — Channel partners in Japan, Singapore, Hong Kong, Thailand, and other select markets that sell and promote the therapy locally. - **Veterans Health Administration** (secondary) — Government healthcare channel that purchases under contract for eligible patients. - Hospitals and ASCs buy the system for implantation procedures - ENT physicians influence adoption and patient selection - Sleep centers help diagnose and route eligible OSA patients - Commercial insurers and Medicare shape reimbursement access - Veterans Health Administration is a government customer pathway ## Geography Revenue is heavily concentrated in the United States, which represented 95.6% of 2025 revenue, while all other countries contributed 4.4%. Outside the U.S., the company sells directly in select European markets and Japan, and through distributors in parts of Asia-Pacific, which makes international growth dependent on local regulatory approvals, reimbursement, and channel execution. - **United States** (95.6%) — 2025 annual revenue - **All other countries** (4.4%) — 2025 annual revenue; includes Europe and Asia-Pacific - United States is the core market and the main revenue driver - Select European markets are served through direct sales - Japan is an approved market and an important international foothold - Singapore, Hong Kong, and Thailand are served through distributors - International growth depends on reimbursement and regulatory access ## Strategy The company is focused on expanding adoption of Inspire therapy through physician education, direct-to-consumer marketing, and broader reimbursement coverage. It is also investing in next-generation products, especially Inspire V, and in regulatory expansion to support growth in additional international markets. - **Scale Inspire V adoption** (short-term) — A newer platform can refresh demand, support upgrades, and improve the product's competitive position. - **Expand reimbursement access** (short-term) — Coverage policies are essential because treatment uptake depends on payor approval and patient affordability. - **Increase patient and physician awareness** (medium-term) — The business relies on referral-driven adoption and patient activation for procedure growth. - **Expand international markets** (medium-term) — Non-U.S. markets are still small but offer long runway if approvals and reimbursement improve. - Expand patient awareness and physician adoption of Inspire therapy - Broaden reimbursement coverage across commercial and government payors - Launch and scale Inspire V to support upgrades and new placements - Extend regulatory approvals into additional European and Asia-Pacific markets - Use direct sales and distributor channels to deepen market penetration ## Risks The company is highly dependent on a single product franchise, so adoption, reimbursement, and competitive pressure directly affect growth. It also faces execution risk from direct sales scaling, surgeon capacity constraints, cybersecurity exposure, and foreign market complexity, while emerging alternatives such as GLP-1 drugs and competing OSA devices could slow penetration. - **Product concentration** [high] — Nearly all revenue comes from one therapy platform, so any slowdown in adoption or product issues would affect results materially. - **Reimbursement and coverage risk** [high] — The therapy depends on third-party payor approval, prior authorization, and coverage policy maintenance. - **Competitive substitution** [medium] — Alternative OSA treatments, including GLP-1 drugs and competing neurostimulation devices, may divert patients or physicians. - **Sales force and capacity constraints** [medium] — Growth depends on a large direct sales organization and enough trained surgeons to perform procedures. - **Cybersecurity and IT disruption** [high] — Core functions such as manufacturing, distribution, and patient data handling rely on IT systems and third parties. - **International regulatory and foreign exchange risk** [medium] — Non-U.S. expansion requires approvals, local compliance, and exposure to currency and trade issues. - Heavy dependence on Inspire system sales creates concentration risk - Reimbursement changes could slow patient access and procedure volume - Competition from GLP-1 drugs and other OSA therapies may reduce demand - Direct sales execution and surgeon capacity can constrain growth - Cybersecurity or IT failures could disrupt operations and sensitive data ## Accounting Revenue is driven by product sales and is sensitive to shipment timing, procedure adoption, and quarter-to-quarter demand swings. Investors should also watch estimates tied to inventory, share-based compensation, taxes on net share settlements, and any impairment or valuation issues as the company continues to invest in new products and international expansion. - **Revenue recognition timing** — Quarterly comparability and reported growth rates - **Inventory and manufacturing-related estimates** — Cost of goods sold and gross margin - **Share-based compensation and tax on net share settlements** — Operating expenses, equity, and cash flow - **Capitalized equipment and tooling for Inspire V** — Balance sheet and future cost structure - Revenue is recognized on product sales, so shipment timing affects quarterly results - Gross margin reflects product mix, manufacturing efficiency, and launch costs - Share repurchases and equity awards create tax and equity accounting effects - Cash and investments are important because the company funds R&D and expansion internally - Capitalized tooling and equipment for Inspire V can affect depreciation and asset values --- *Last updated: 2026-04-28T20:17:39.365088+00:00*